

ENS-CCA / Precision-BTC Network Joint Meeting

June 11-12, 2026

Conference Directors Luke Boulter / Rocio Macias / Chiara Braconi
Local Organizer Konstantinos Athanasopoulos

Day 1	Academia-Pharma Interaction		June 11th 2026
TIME (EEST)	TITLE	SPEAKER	
8:00-8:45	Registration, badge & material delivery		
8:45-9:00	Welcome words	Konstantinos Athanasopoulos (Greece)	
9:00 - 9:15	ENSCCA 10 Years Reflection	Luke Boulter (UK)	
9:15 - 9:30	COST Update/Overview	Rocio Macias (Spain)	
9:30 - 10:45	SESSION 1: TRANSLATION INTO CLINICAL DEVELOPMENT: ROLE OF AI IN BIOMARKERS & DIAGNOSTICS		
	Moderators:	Alejandro Forner (Spain) & Tim Kendall (UK)	
9:30 - 9:40	Challenges in diagnostics of Biliary Tract Cancers	Pedro Rodrigues (Spain)	
9:40 - 10:00	Panel discussion	With the addition of: Jesus Banales (Spain), Stephen Rossi (Spain)	
	Moderators:	Anna Saborowski (Germany) & Victor Moreno (Spain)	
10:00 - 10:10	Example of a biomarker-driven therapeutics: what is the challenge and how can academia help?	Brian Lockhart (Servier)	
10:10 - 10:45	Panel discussion	With the addition of: Stacie Lindsey (USA), Benjamin Goeppert (Germany)	
10:45 - 11:30	Coffee Break		
11:30-13:00	SESSION 2: PATIENT INVOLVEMENT INTO EARLY TRIALS		
	Moderators:	Angela Lamarca (Spain) & John Bridgewater (UK)	
11:30-11:40	Challenges of rare cancers in clinical trials	Arndt Vogel (Germany)	
11:40-11:50	Challenges of rare cancers in clinical trials	Katherine Baria (Jazz Pharmaceuticals)	
11:50-12:00	Phase I trials - Patient views: how can patient advocacy groups impact on trial design?	Juan Valle (USA)	
12:10-12:20	IDH success trial phase 1: how did it develop?	Lorenza Rimassa (ILCA member, Italy)	
12:20-12:30	How to make academic trials with on-patent drugs successful	John Bridgewater (UK)	
12:30 - 13:00	Panel discussion	With the addition of: Paul Howard (AMMF), Matteo Fassan (Italy)	
13:00 - 14:30	Lunch Break		
14:30 - 15:30	Oral Abstracts		
	Moderators:	Rui Castro (Portugal) & Mairead McNamara (UK)	
15:30 - 16:15	KEYNOTE TALK		
	Introduction	Chiara Braconi (UK)	
	Therapeutic development: directions from basic research	Tim Greten (USA)	
16:15 - 17:25	SESSION 3: DRUG DEVELOPMENT: NEW TARGETS & COMPOUNDS TO CLINIC		
	Moderators:	Teresa Macarulla (Spain) & Tim Greten (USA)	
16:15-16:25	Approach from Big Pharma: what are you looking for when you invest in a new compound?	Caleb Briggs (AstraZeneca)	
16:25-16:35	Approach from Smaller Biotech: the evolution from academia to industry	Flavia Scialpi (Trogenix, UK)	
16:35-16:45	ADCs: where are we going?	Victor Moreno (Spain)	
16:45-16:55	Drug development in a patients' niche: how to collaborate between industry and academia?	Kristin Ryan (Elevar Therapeutics, USA)	
16:55-17:05	Supporting devices for drug discovery	Ana Lleo (Italy)	
17:05 - 17:25	Panel Discussion	With the addition of: Tian Tian (Spain)	
17:25 - 18:15	Poster Tour		
	Moderators:	Konstantinos Athanasopoulos (Greece), Pilar Acedo (UK) & Jerzy Kotlinowski (Poland)	
20:00	Joint Dinner		

Day 2	Precision-BTC Network Annual Conference		June 12th 2026
TIME	TITLE		SPEAKER
8:00 - 8:30	Registration, badge & material delivery		
8:30 - 9:30	SESSION 1: WG1 - IDENTIFICATION OF EPIDEMIOLOGICAL HETEROGENEITY IN EUROPE		
	<i>Moderators:</i> <i>Marcin Krawczyk (Poland) & Lewis Roberts (USA)</i> 10 minute presentation + 5 minute discussion		
8:30 - 8:45	Stromal drivers of metastatic niche formation in cholangiocarcinoma		Veronika Lukacs-Kornek (Germany)
8:45 - 9:00	GLOBAL-BTC Registry: Expanding the Understanding of Cancer Across the Biliary Tract		Laura Izquierdo-Sanchez (Spain)
9:00 - 9:15	A machine learning-powered tool to characterize CCA prognosis		Lorenzo Manganaro (Italy)
9:15 - 9:30	Personalize prevention for CCA in PSC patients		Shahid Khan (UK)
09:30 - 10:30	SESSION 2: WG2 - PERSONALISED EARLY DETECTION OF BTC		
	<i>Moderators:</i> <i>Guido Carpino (Italy) & Stephanie Roessler (Germany)</i> 10 minute presentation + 5 minute discussion		
9:30 - 9:45	Molecular diagnostic solutions for detection of malignant biliary strictures		Michael Dill (Germany)
9:45 - 10:00	Novel blood metabolomic tests for the diagnosis of primary sclerosing cholangitis and associated CCA		Ainhoa Lapitz (Spain)
10:00 - 10:15	Proteomic Profiling of Circulating Early Detection Biomarkers in PSC and CCA		Rebeca Correa González (UK)
10:15 - 10:30	Extracellular matrix remodeling links PSC to cholangiocarcinoma in a sex-dependent manner		Camilla Venturin (Italy)
10:30-11:00	Coffee Break & Group Photo		
11:00 - 12:00	SESSION 3: WG3 - PERSONALISATION OF TREATMENT FOR PATIENTS WITH BTC		
	<i>Moderators:</i> <i>Anna Saborowski (Germany) & Elene Mariamidze (Georgia)</i> 10 minute presentation + 5 minute discussion		
11:00 - 11:15	Biomarker of adjuvant chemotherapy: data from the BILCAP		Chiara Braconi (UK)
11:15 - 11:30	Insights from the real world data from the international community: strategizing the chemoimmunotherapy		Andrea Casadei-Gardini (Italy)
11:30 - 11:45	Route of diagnosis, onset of symptoms and potential areas of improvement in BTC		Andrea Martirena (Spain)
12:00 - 13:00	SESSION 4: WG4 - PATIENT-CENTRIC SUPPORT MANAGEMENT		
	<i>Moderators:</i> <i>Ana Lleo (Italy) & Mohamed Bouattour (France)</i> 10 minute presentation + 5 minute discussion		
12:00 - 12:15	The role of nurse in Europe		Gemma Iserte (Spain)
12:15 - 12:30	Precision-BTC and EORTC: ongoing collaboration		Antonella Cammarota (Italy)
12:30 - 12:45	Bringing patients' voices to the UK government		Helen Morement (UK)
12:45 - 13:00	Shining light on hidden cancers: BTC in Europe		Elisabeth Baucells (Spain)
13:00-14:30	Lunch Break		
14:30-15:30	SESSION 5: WG5 - ARTIFICIAL INTELLIGENCE		
	<i>Moderator:</i> <i>Jesper B Andersen (Denmark) & Ghada Nouairia (Sweden)</i> 10 minute presentation + 5 minute discussion		
14:30 - 14:45	Update on the molecular registry		Colm O'Rourke (Denmark)
14:45 - 15:00	AI in iCCA: From Diagnosis to treatment decisions		Stefano Caruso (France)
15:00 - 15:15	Genome-wide methylation profiling from BTCs and PSC using blood DNA provides diagnostic, prognostic tools and biological insights		Ghada Nouairia (Sweden)
15:30-16:30	SESSION 6: WG6 - DRUG DEVELOPMENT USING PRECLINICAL MODELS		
	<i>Moderators:</i> <i>Marta Afonso (Portugal) & Attila Hunyadi (Hungary)</i> 10 minute presentation + 5 minute discussion		
15:30 - 15:45	Targeting the stroma (TBD)		Silvia Affo (Spain)
15:45 - 16:00	Drug discovery with patients derived organoids (TBD)		Daniela Sia (Mount Sinai, USA)
16:00 - 16:15	Early Neoplastic Transition States as Targets for Precision Prevention		Ed Jarman (UK)
16:15 - 16:30	Anticancer activity of RAS-GTP inhibition in CCA		Konstantina Morali (Spain)
16:30 - 16:35	Closing remarks and farewell		